Navigation Links
BD Receives FDA Approval for the BD FocalPoint(TM) GS Imaging System to Enhance the Detection of Cervical Cancer
Date:12/4/2008

BURLINGTON, N.C., Dec. 4 /PRNewswire-FirstCall/ --BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint(TM) GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath(TM) Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

"The launch of the BD FocalPoint(TM) GS System represents a key milestone in our effort to expand BD's presence in cancer diagnostics," said Vincent A. Forlenza, BD Executive Vice President. "It is the first in a series of innovative products aimed at improving the detection and clinical management of cancer, resulting from our TriPath acquisition."

Despite significant improvements in cervical cancer screening over the past 40 years, nearly 4,000 women die from the disease each year in the United States, and costs to treat the disease exceed $2 billion annually. The key to detecting cervical cancer early is regular Pap testing. However, limitations exist with current technologies. Approximately one-third of Pap smear false negatives can be attributed to screening and interpretive errors in which abnormal cells are incorrectly classified.

The new BD FocalPoint(TM) GS Imaging System seeks to address this problem by offering laboratories key advantages over current cervical cancer imaging systems. Its state-of-the-art guided screening (GS) technology helps rapidly relocate the fields of view that the system has identified as the most likely to contain cells of interest.

"Our clinical trial results give us confidence that the BD FocalPoint(TM) GS Imaging System will provide cytology labs with the advanced tool they need to improve cervical cancer detection and enhance their productivity," said Wayne Brinster, Vice President and General Manager, BD Diagnostics - TriPath. "It demonstrates BD's commitment to providing innovative, world-class products and services for the oncology market that help improve patient outcomes by offering clinicians better tools to detect and manage disease."

About BD

BD, a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases and cancer, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.


'/>"/>
SOURCE BD-Becton Dickinson
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative ... National Family Partnership and the Drug Enforcement Administration as part of the National Red ... 10 winning schools who decorated their campuses with this year’s Red Ribbon Week theme: ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For ... announced the opening of a new residential mental health treatment program in Chino ... issues such as severe anxiety, depression, bi-polar disorder, and other related issues. , ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für ... Apothekenbundes von Kenia eingeführt. Continue Reading ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic Implants ... Support) is Expected to Gain a Significant Market Share Owing ... Ailments  ... According to a new ... Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected to ...
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... in red, while the Dow Jones Industrial Average managed to ... of US markets, which prompted Stock-callers this morning to look ... (NASDAQ: NUVA ), Smith & Nephew PLC (NYSE: ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: KOOL ...
Breaking Medicine Technology: